Log In
BCIQ
Print this Print this
 

SCIB1

  Manage Alerts
Collapse Summary General Information
Company Scancell Holdings plc
DescriptionCancer vaccine comprising the melanoma antigen tyrosinase-related protein 2 (TRP-2; TYRP2; DCT) and 2 helper T cell epitopes
Molecular Target Tyrosinase-related protein 2 (TRP-2) (TYRP2) (DCT)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationMelanoma
Indication DetailsTreat melanoma; Treat stage III/IV metastatic melanoma
Regulatory Designation U.S. - Orphan Drug (Treat melanoma)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/30/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today